Safi Biotherapeutics

Safi Biotherapeutics is a private, pre-clinical stage biotech founded in 2020 to address global blood shortages by manufacturing red blood cells at scale. Leveraging over $20M in non-dilutive government funding and strategic partnerships, the company has developed a proprietary biomanufacturing process for high-density mRBC production and is exploring advanced cryopreservation. With key regulatory designations for sickle cell disease and a clear path toward clinical trials, Safi is positioning itself as a leader in the field of cellular therapeutics for transfusion medicine.

Proprietary biomanufacturing platform for producing adult stem cell-derived red blood cells (mRBCs) at high densities in bioreactors, with advanced research into glycerol-free cryopreservation and freeze-drying for long-term storage.

Safi operates in the emerging field of cultured red blood cells, competing with other biotechs like Rubius Therapeutics (shifted focus), and academic consortia. Its primary competitive advantages are its advanced 10L GMP manufacturing scale, focused research on deployable formats (freeze-drying), and unique, well-funded partnership with the U.S. Department of Defense. Larger pharmaceutical companies may enter the space via partnership or acquisition once clinical proof-of-concept is achieved.